Jaan Biotherapeutics Receives National Heart, Lung, and Blood Institute Phase II SBIR Award

(Isstories Editorial):- San Diego, California Oct 6, 2025 (Issuewire.com) – Jaan Biotherapeutics, Inc., a privately held biopharmaceutical company based in San Diego, California, focused on developing novel treatments for heart disease, has been awarded a Phase II SBIR grant of $2.89M from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The grant supports pre-clinical development of JBT-miR2, a microRNA targeting treatment, for the treatment of ischemic heart disease (IHD), following an acute myocardial infarction.

More on Isstories:

• Reliable Commercial Cleaning with Eco and Traditional Options–Eco Fresh Cleaning Team Delivers Both
• Where Others Compromise, We Innovate: Teleport Ride Sets a New Standard
• Scott M. Alexander Releases Q3 2025 Digital Transformation Insights Report: “Convergence = Resilience”
• Bay Area Painter Easton Cain Announces “Parabolic” for 2026 After Surf Injury
• New Book Demystifies the Complexities of New Car Warranties

The world’s biggest killer is IHD, responsible for 13% of the world’s total deaths. There are approximately 315 million people living with IHD globally. The prevalence of IHD is expected to increase by ~30% reaching 28.7 million people in the U.S. by 2060 with the aging population.

IHD can be caused by significant permanent loss of heart muscle, following a heart attack, making the heart weaker, unable to supply blood and oxygen to the tissues and organs, leading to heart failure and eventual death. There is no therapy that can regenerate functional heart muscle to treat IHD. JBT-miR2 endogenously regenerates heart muscle within the damaged heart by activating fetal cardiac muscle regenerative pathways.

This grant will enable the company to determine the best way to administer the drug to those people who are at “high-risk” of death.

“We are grateful to the NIH for their continued support of our studies and our novel approach. We are excited about the prospects of moving into clinical trials and the potential impact this could have on millions of patients in the U.S. and worldwide.”

Research reported in this release is supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R44HL180034. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article was originally published by IssueWire. Read the original article here.